STAAR Surgical short report ‘comes up short,’ says Benchmark

After a short report alleged that STAAR Surgical engaged in channel stuffing with their distributor in China, Benchmark analyst Bruce Jackson stated that he believes the allegations are unlikely. In a note to investors entitled “Report Asserting Channel Stuffing Comes Up Short,” Jackson said STAAR ships large amounts of product to China since “it is the largest market in the world for surgical vision correction” and one that is “nowhere near saturation.” The analyst, who said he is watching Chinese consumer confidence and tariffs, added that “unsupported conspiracy theories are not on our list.” He keeps a Buy rating and $54 price target on STAAR shares and would be a buyer on the weakness caused by the short report.

https://thefly.com/landingPageNews.php?id=2865554